+

WO2003011214A3 - Nouvelles methodes et formulations concues pour administrer des agents actifs - Google Patents

Nouvelles methodes et formulations concues pour administrer des agents actifs Download PDF

Info

Publication number
WO2003011214A3
WO2003011214A3 PCT/US2002/021646 US0221646W WO03011214A3 WO 2003011214 A3 WO2003011214 A3 WO 2003011214A3 US 0221646 W US0221646 W US 0221646W WO 03011214 A3 WO03011214 A3 WO 03011214A3
Authority
WO
WIPO (PCT)
Prior art keywords
formulations
administration
active agents
novel methods
conditioning agent
Prior art date
Application number
PCT/US2002/021646
Other languages
English (en)
Other versions
WO2003011214A2 (fr
Inventor
Garfield P Royer
Joseph A Manda
Original Assignee
Royer Biomedical Inc
Garfield P Royer
Joseph A Manda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royer Biomedical Inc, Garfield P Royer, Joseph A Manda filed Critical Royer Biomedical Inc
Priority to AU2002322424A priority Critical patent/AU2002322424A1/en
Publication of WO2003011214A2 publication Critical patent/WO2003011214A2/fr
Publication of WO2003011214A3 publication Critical patent/WO2003011214A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0063—Periodont
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne en général la production et l'utilisation de complexes composés inorganiques-agents modificateurs servant à réguler la libération de composés comprenant des produits médicinaux. De manière avantageuse, le produit inorganique utilisé est le sulfate de calcium et l'agent modificateur est le stéarate de calcium.
PCT/US2002/021646 2001-07-31 2002-02-26 Nouvelles methodes et formulations concues pour administrer des agents actifs WO2003011214A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002322424A AU2002322424A1 (en) 2001-07-31 2002-02-26 Novel methods and formulations for administration of active agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30859301P 2001-07-31 2001-07-31
US60/308,593 2001-07-31

Publications (2)

Publication Number Publication Date
WO2003011214A2 WO2003011214A2 (fr) 2003-02-13
WO2003011214A3 true WO2003011214A3 (fr) 2009-06-11

Family

ID=23194577

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/021646 WO2003011214A2 (fr) 2001-07-31 2002-02-26 Nouvelles methodes et formulations concues pour administrer des agents actifs

Country Status (2)

Country Link
AU (1) AU2002322424A1 (fr)
WO (1) WO2003011214A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2533896A1 (fr) * 2003-07-28 2005-02-10 Mallinckrodt, Inc. Composition de stearate amelioree et procede
EP1680089B1 (fr) 2003-10-22 2013-09-11 Lidds AB Composition comprenant des ceramiques d'hydratation biodegradables pour une administration de medicaments controlee
CA2575497A1 (fr) * 2004-07-28 2006-03-02 Mallinckrodt Inc. Composition de stearate amelioree et procede
NZ552290A (en) 2006-12-21 2009-05-31 Bomac Research Ltd Tablet fomulation
RU2497679C2 (ru) 2008-10-02 2013-11-10 Милан Инк. Способ получения многослойного клеящегося ламинированного материала

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781268A (en) * 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
WO1999015150A1 (fr) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Complexes inorganiques-polymeres utiles pour une liberation controlee de composes comprenant des composes medicinaux
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3781268A (en) * 1972-01-27 1973-12-25 Bristol Myers Co Antibiotic derivatives of kanamycin
WO1999015150A1 (fr) * 1997-09-22 1999-04-01 Buford Biomedical, Inc. Complexes inorganiques-polymeres utiles pour une liberation controlee de composes comprenant des composes medicinaux
US6497901B1 (en) * 2000-11-02 2002-12-24 Royer Biomedical, Inc. Resorbable matrices for delivery of bioactive compounds

Also Published As

Publication number Publication date
AU2002322424A8 (en) 2009-07-30
WO2003011214A2 (fr) 2003-02-13
AU2002322424A1 (en) 2003-02-17

Similar Documents

Publication Publication Date Title
CA2303884A1 (fr) Complexes inorganiques-polymeres utiles pour une liberation controlee de composes comprenant des composes medicinaux
PL367277A1 (en) Methods of making sustained release formulations of oxymorphone related applications
MXPA02012712A (es) N-ureidoheterocicloalquil-piperidinas como moduladores de la actividad del receptor de quimiocinas.
DE60112974D1 (en) Carbolinderivate
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
AU2000279625A1 (en) Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
WO2003024401A3 (fr) Piperazinones de modulation de l'activite des recepteurs des chimiokines
DE60216233D1 (en) Carbolinderivate
MXPA03010761A (es) Combinaciones farmaceuticas.
AU2001266575A1 (en) Chemical compounds
MXPA03002911A (es) Compuestos quimicos.
WO2002051983A3 (fr) Composes et compositions en tant qu'inhibiteurs de cathepsine
WO2002070469A3 (fr) Inhibiteurs selectifs de pde3b et leurs utilisations therapeutiques
WO2002096368A3 (fr) Encapsulation de nanosuspensions dans des liposomes et des microspheres
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
WO2001098270A3 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
WO2001098269A3 (fr) N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
WO2001074394A8 (fr) Nouvelle combinaison d'un betabloquant et d'un hypocholesterolemiant
WO2003011214A3 (fr) Nouvelles methodes et formulations concues pour administrer des agents actifs
CA2399709A1 (fr) Utilisation d'acide 2-methyl-thiazolidin-2,4-dicarboxylique (2-mtdc) et/ou de ses sels physiologiquement compabibles pour le traitement et/ou la prevention de cancers
CA2445620A1 (fr) Composes tetracycliques utilises comme inhibiteurs de pde5-
WO2004048381A3 (fr) Nouveaux composes de pyrazoloazepine utilises en tant qu'agents pharmaceutiques
AU2002254930A1 (en) Novel medicament compositions based on anticholinergic agents and endothelin antagonists
WO2002036105A3 (fr) Utilisation d'agents sequestrants de cortisol dans le cadre du traitement de troubles lies a l'hypercortisolemie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE CH CY DE DK FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载